Table of Contents

Research Briefs

• Research Briefs | AuthorChoice

  A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

  Alexander Drilon, Ramamoorthy Nagasubramanian, James F. Blake, Nora Ku, Brian B. Tuch, Kevin Ebata, Steve Smith, Veronique Lauriault, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Paul D. Larsen, Karyn S. Bouhana, Shannon L. Winski, Robyn Hamor, Wen-I Wu, Andrew Parker, Tony H. Morales, Francis X. Sullivan, Walter E. DeWolf, Lance A. Wollenberg, Paul R. Gordon, Dorothea N. Douglas-Lindsay, Maurizio Scaltriti, Ryma Benayed, Sandeep Raj, Bethany Hanusch, Alison M. Schram, Philip Jonsson, Michael F. Berger, Jaclyn F. Hechtman, Barry S. Taylor, Steve Andrews, S. Michael Rothenberg and David M. Hyman

  Cancer Discov September 1 2017 7 (9) 963-972; DOI:10.1158/2159-8290.CD-17-0507

  
  

  Parallel development of the first-generation TRK TKI larotrectinib with the next-generation TKI LOXO-195 allowed for rapid use of LOXO-195 to treat patients with acquired larotrectinib resistance.

• Research Briefs

  Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations

  Franklin W. Huang, Juan Miguel Mosquera, Andrea Garofalo, Coyin Oh, Maria Baco, Ali Amin-Mansour, Bokang Rabasha, Samira Bahl, Stephanie A. Mullane, Brian D. Robinson, Saud Aldubayan, Francesca Khani, Beerinder Karir, Eejung Kim, Jeremy Chimene-Weiss, Matan Hofree, Alessandro Romanel, Joseph R. Osborne, Jong Wook Kim, Gissou Azabdaftari, Anna Woloszynska-Read, Karen Sfanos, Angelo M. De Marzo, Francesca Demichelis, Stacey Gabriel, Eliezer M. Van Allen, Jill Mesirov, Pablo Tamayo, Mark A. Rubin, Isaac J. Powell and Levi A. Garraway

  Cancer Discov September 1 2017 7 (9) 973-983; DOI:10.1158/2159-8290.CD-16-0960

  
  

  Sequencing of an African-American prostate cancer cohort identified ERF as a tumor suppressor in prostate cancer and shows that increasing ethnic diversity enhances the discovery of potential cancer drivers.

• Research Briefs | AuthorChoice

  Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

  Olga Kondrashova, Minh Nguyen, Kristy Shield-Artin, Anna V. Tinker, Nelson N.H. Teng, Maria I. Harrell, Michael J. Kuiper, Gwo-Yaw Ho, Holly Barker, Maria Jasin, Rohit Prakash, Elizabeth M. Kass, Meghan R. Sullivan, Gregory J. Brunette, Kara A. Bernstein, Robert L. Coleman, Anne Floquet, Michael Friedlander, Ganessan Kichenadasse, David M. O'Malley, Amit Oza, James Sun, Liliane Robillard, Lara Maloney, David Bowtell; on behalf of the AOCS Study Group, Heidi Giordano, Matthew J. Wakefield, Scott H. Kaufmann, Andrew D. Simmons, Thomas C. Harding, Mitch Raponi, Iain A. McNeish, Elizabeth M. Swisher, Kevin K. Lin and Clare L. Scott

  Cancer Discov September 1 2017 7 (9) 984-998; DOI:10.1158/2159-8290.CD-17-0419

  
  

  In patients with high-grade ovarian carcinoma treated with the PARP inhibitor rucaparib, secondary reversion mutations in HR genes restore the open reading frame and HR activity to confer resistance.

• Research Briefs | AuthorChoice

  Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors

  David Quigley, Joshi J. Alumkal, Alexander W. Wyatt, Vishal Kothari, Adam Foye, Paul Lloyd, Rahul Aggarwal, Won Kim, Eric Lu, Jacob Schwartzman, Kevin Beja, Matti Annala, Rajdeep Das, Morgan Diolaiti, Colin Pritchard, George Thomas, Scott Tomlins, Karen Knudsen, Christopher J. Lord, Charles Ryan, Jack Youngren, Tomasz M. Beer, Alan Ashworth, Eric J. Small and Felix Y. Feng

  Cancer Discov September 1 2017 7 (9) 999-1005; DOI:10.1158/2159-8290.CD-17-0146

  
  

  Multiclonal BRCA2 reversion mutations were detected in circulating cell-free DNA from two patients with metastatic prostate cancer after PARP inhibitor treatment, suggesting a mechanism of resistance.